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Abstract
Background: The catechol-O-methyltransferase (COMT) gene contains a functional
polymorphism, Val158Met, which has been linked to anxiety and depression, but previous results
are not conclusive. The aim of the present study was to examine the relationship between the
Val158Met COMT gene polymorphism and anxiety and depression measured by the Hospital
Anxiety and Depression Scale (HADS) in the general adult population.
Methods: In the Nord-Trøndelag Health Study (HUNT) the association between the Val158Met
polymorphism and anxiety and depression was evaluated in a random sample of 5531 individuals.
Two different cut off scores (≥ 8 and ≥ 11) were used to identify cases with anxiety (HADS-A) and
depression (HADS-D), whereas controls had HADS-A <8 and HADS-D <8.
Results: The COMT genotype distribution was similar between controls and individuals in the
groups with anxiety and depression using cut-off scores of ≥ 8. When utilizing the alternative cut-
off score HADS-D ≥ 11, Met/Met genotype and Met allele were less common among men with
depression compared to the controls (genotype: p = 0.017, allele: p = 0.006). In the multivariate
analysis, adjusting for age and heart disease, depression (HADS-D ≥ 11) was less likely among men
with the Met/Met genotype than among men with the Val/Val genotype (OR = 0.37, 95% CI =
0.18–0.76).
Conclusion: In this population-based study, no clear association between the Val158Met
polymorphism and depression and anxiety was revealed. The Met/Met genotype was less likely
among men with depression defined as HADS-D ≥ 11, but this may be an incidental finding.
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The catechol-O-methyltransferase (COMT) gene located
on chromosome 22q11.2 contains a common functional
polymorphism at codon 158. This polymorphism has
been subject to a large number of studies, due to the
COMT enzyme's important role in the metabolism of cat-
echolamines (1). A substitution of valine (Val) by methio-
nine (Met) at codon 158 affects the activity of the COMT
enzyme, and individuals with the Val/Val genotype have a
3–4-times higher enzyme activity than those with the
Met/Met genotype [1]. Since the alleles are co-dominant,
heterozygous individuals (Val/Met) show an enzyme
activity halfway between the homozygous genotypes.
The Val158Met polymorphism has been linked to a broad
range of psychiatric disorders including anxiety and mood
disorders [2]. Although anxiety and depression both are
influenced by several genes in combination with environ-
mental factors, association studies with large samples of
subjects are appropriate for searching susceptibility genes
with minor effects on these disorders [3]. A large Euro-
pean multicenter study including 1512 participants
reported an association between the Val/Val genotype and
major depression with early onset [3], but conflicting
results have been found in other studies with fewer partic-
ipants [4]. Similarly, inconsistent findings have also been
reported in studies evaluating the relationship between
the Val158Met polymorphism and anxiety [5-7]. Ethnic
heterogeneity and gender specificity may have influenced
on the inconclusive results [8].
Most of the previous studies evaluating the relationship
between the Val158Met polymorphism and anxiety and/
or mood disorders have been case-control studies. In such
studies undiagnosed- and untreated cases with depression
and/or anxiety may have been missed. Generalization of
the results should therefore be done with caution. Because
population-based studies have the potential to intercept
undiagnosed- and untreated cases [9], the influence of the
Val158Met polymorphism on anxiety and depression
should also be evaluated in the general population.
To the best of our knowledge, this is the first population-
based study evaluating the relationship between the
Val158Met polymorphism and anxiety and depression
measured by the Hospital Anxiety and Depression Scale
(HADS). The dimensional structure of HADS has been
found stable across age-groups [9], and the HADS ques-
tionnaire is widely used to measure anxiety and depres-
sion in somatic and psychiatric patients as well as in the
general population [10]. Previous studies on HADS have
shown good reliability and validity compared to other
symptom scales of depression and anxiety [10-15].
In the present study, we examined the relationship
between the Val158Met polymorphism and anxiety and
depression measured by HADS in a population-based
cohort of 5531 subjects.
Methods
Study population
Between August 1995 and June 1997, all inhabitants aged
20 years or older in Nord-Trøndelag County were invited
to participate in the Nord-Trøndelag Health Study
(HUNT). In brief, two questionnaires including more
than 200 health related questions were administrated to
the participants. The population in Nord-Trøndelag
County was ethnically homogenous (less than 3% of sub-
jects were of non-Caucasian ethnicity), making it suitable
for epidemiological genetic research [16].
Out of 92,936 invited individuals, a total of 65,291 sub-
jects (70%) answered the first questionnaire and partici-
pated in a health examination. The first questionnaire
included questions about e.g. vascular diseases, smoking,
and physical activity [16]. The health examination
included measurements of height, weight, and blood
pressure, and blood samples measuring e.g. cholesterol
were collected [16].
Details of the non-participants are described elsewhere
[17]. Blood samples were collected from 62,664 of the
study population whenever they attended, and stored at
HUNT 2 Biobank [16]. In 2002, all surviving participants
(n = 61,426) were asked for permission to use the blood
samples in genetic analyses. Over 98% (n = 60,241)
accepted this [16]. Analyses on the Val158Met polymor-
phism have been carried out on 5,531 participants, of
whom 4513 (82%) were selected completely at random.
The first 1018 (18%) subjects were randomly selected
among an older group who did not have self-reported dia-
betes mellitus [18]. This group was generated in connec-
tion with a planned genetic study on diabetes that needed
age-matched controls to a diabetic population. As a con-
sequence, the prevalence of self-reported diabetes mellitus
was somewhat lower among individuals with known gen-
otype than among those without COMT data available
(1.3% versus 3.2%, p < 0.001).
Genotyping
DNA for genotyping was extracted from peripheral blood
leukocytes from EDTA whole blood or blood clots, stored
in the HUNT 2 Biobank, manually with the use of Pure-
gene kit (Gentra Systems Inc., Minneapolis, MN) or with
the Autopure LS (Gentra Systems Inc., Minneapolis, MN).
The laboratory technicians were blinded for other HUNT
data. Genotypes of the COMT Val158Met polymorphism
were determined using a LightCycler Real Time PCR
machine (Roche Diagnostics Scandinavia AB, Bromma,Page 2 of 8
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reagent on a LightCycler System by using 2 μL genomic
DNA and LightCycler-FastStart DNA Master Hybridiza-
tion Probes kit (Roche Diagnostics, Bromma, Sweeden).
Details on PCR primers and hybridization probes used
have been published elsewhere [17]. Based on melting-
curve profiles, the genotypes of the participants were clas-
sified as Val/Val, Val/Met or Met/Met.
Anxiety and depression
HADS is a self-assessment scale containing 14 questions
developed to detect states of anxiety and depression, spe-
cifically designed for non-psychiatric hospital depart-
ments [20]. To each question there are four possible
response options which are scored from 0 to 3 points
depending on the severity of the symptoms. There are
seven questions related to depressive symptoms (HADS-D
subscale) and seven questions concerning anxiety symp-
toms (HADS-A subscale). Based on empirical knowledge
a clinically significant anxiety disorder is defined by a
HADS-A score of ≥ 8, while depressive disorder is defined
by HADS-D ≥ 8. These limits are found to give the optimal
balance between sensitivity and specificity [11]. Based on
HADS-A and HADS-D scores, the participants were classi-
fied into one of five groups: 1) No disorder (controls):
both HADS-A <8 and HADS-D <8; 2) Anxiety disorder:
HADS-A ≥ 8; 3) Depressive disorder: HADS-D ≥ 8; 4)
Combined disorder: both HADS-A ≥ 8 and HADS-D ≥ 8;
and 5) Unclassified. This last group consisted of subjects
with insufficient HADS score data. Some had total HADS
scores but unavailable subscale scores, while others only
had valid HADS-A or HADS-D score. To increase the spe-
cificity [9] and with intention identify individuals with
moderate or severe disorder, analyses using cut-off score ≥
11 were also performed, recommended for the first time
25 years ago [21]. Analyses were performed for men and
women separately because previous studies have reported
a gender difference regarding anxiety and the Val158Met
polymorphism [8].
Ethics
The study was approved by the Regional Committee of
Ethics, by the Norwegian Data Inspectorate and by the
Directorate for Health and Social Affairs.
Statistical analyses
Baseline data were compared between genotype status
with analyses of variance (one-way ANOVA) for continu-
ous variables and with Pearson's chi-square test for cate-
gorical variables. Blood pressure values were compared
with the non-parametric Mann-Whitney U test because of
a skewed distribution of the data [18].
Gender comparisons for each genotype regarding HADS-
A scores and HADS-D scores as continuous variables were
performed with Mann-Whitney U because of skewed data.
Spearman's correlation analyses were conducted to corre-
late scores of HADS-A and HADS-D with genotypes.
Chi-square test was used to evaluate dichotomous varia-
bles of HADS-A and HADS-D. Binary multivariate logistic
regression was used to estimate odds ratios (OR) for the
association between genotype and each of the two HADS
subscales, i.e. depression and anxiety disorder (dependent
variable). Potential confounding was evaluated by adjust-
ing for sex, age (5-year categories) and ischemic heart dis-
ease. The precision for the OR was estimated with 95%
confidence interval (CI).
Two-tailed estimations of significance were used, and the
level of significance was set at p < 0.05.
Overall, our sample of 5,531 had more than 90% power
to detect a 3% difference in prevalence of anxiety and
depression between genotypes with 95 percent certainty.
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS), version 14.0 (SPSS
Inc, Chicago, IL).
Results
The genotype distribution among the 5,531 individuals
was in Hardy-Weinberg equilibrium. Demographic data
of the different genotype groups are shown in Table 1. No
significant difference in gender, age, education level, body
mass index, cholesterol level, smoking status, level of
physical activity, diabetes-, stroke- or headache prevalence
was found between the genotype groups. However, indi-
viduals with Val/Val genotype had lower prevalence of
myocardial infarction (2.3% versus 3.6%, p < 0.05) and
ischemic heart disease (myocardial infarction and/or
angina pectoris) (5.7% versus 7.7%, p = 0.02) compared
to those with the other genotypes (Table 1). The individ-
uals with known genotype were significantly older and
had, consequently, higher blood pressure and cholesterol
level, higher prevalence of ischemic heart disease and
chronic musculoskeletal pain, and had lower physical
activity level than those with unknown COMT genotype
(Table 1).
Mean HADS-D and HADS-A scores related to genotype are
displayed in Figure 1 and in Figure 2, respectively. As dem-
onstrated, the genotype distribution of the scores tended
to differ by gender, most prominent for HADS-A. How-
ever, no significant correlations between genotypes and
scores of HADS-A and HADS-D were found for men or
women.
The distribution of genotypes and alleles of the
Val158Met polymorphism by gender failed to detect a dif-Page 3 of 8
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depression using the cut-off score ≥ 8 for HADS-A and
HADS-D. When utilizing the alternative cut-off score ≥ 11,
the Met/Met genotype and Met allele were less common
among men with depression compared to the controls
(genotype: 18.3% versus 33.9%, p = 0.017; allele: 46.5%
versus 58.1%, p = 0.006) (Table 2). In the multivariate
analysis, adjusting for age and heart diseases, HADS-D ≥
11 was less likely among men with the Met/Met genotype
than among men with the Val/Val genotype (OR = 0.37,
95% CI = 0.18–0.76). For women, this tendency was less
clear (OR = 0.89, 95% CI 0.48–1.63). However, for both
genders combined, depression was less common for the
Met/Met genotype (OR = 0.60, 95% CI = 0.38–0.95).
Mean HADS-A scores with 95% confidence interval related to COMT genotype in men and womenFigure 2
Mean HADS-A scores with 95% confidence interval 
related to COMT genotype in men and women. Num-
bers of participants are given. Gender comparison for each 
genotype was performed with Mann-Whitney U test.
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Table 1: COMT genotypes related to sex, mean age, education > 12 years, mean systolic and diastolic blood pressure, and several 
factors associated with hypertension.
No COMT genotyping Met/Met Val/Met Val/Val
Characteristics (n = 60,072) (n = 1769) (n = 2726) (n = 1036)
Sex, female (%) 53.1 53.7 54.3 56.1
Age, mean (SD) 49.2 (17.3)1 50.7 (17.9) 50.7 (18.0) 50.2 (17.7)
Education > 12 years (%) 19 18 18 18
Median systolic blood pressure (mmHg) 1341 136.5 136 136
Median diastolic blood pressure (mmHg) 791 80 80 80
Body mass index, kg/m2 (SD) 26.4 (4.1) 26.4 (4.1) 26.3 (4.1) 26.3 (4.2)
Cholesterol, mmol (SD) 5.89 (1.26)1 5.96 (1.30) 5.96 (1.30) 6.02 (1.33)
Current smoking (%) 28.2 27.9 28.4 29.6
High level of physical activity (%) 15.81 13.9 14.1 14.8
Diabetes mellitus (%) 3.21 1.3 1.3 1.1
Myocardial infarction (%) 3.3 3.8 3.4 2.32
Angina pectoris (%) 5.01 6.7 5.8 5.1
Stroke (%) 1.9 2.1 1.8 1.8
Headache (%) 38.6 39.7 40.0 37.9
Chronic musculoskeletal pain (%) 46.31 46.4 50.5 48.6
1. Genotyped versus not genotyped: p < 0.003.
2. Val/Val versus other genotypes: p = 0.046.
Heart disease (myocardial infarction and/or angina pectoris):
Val/Val versus other genotypes: p = 0.02 Genotyped versus not genotyped: p < 0.02
Mean HADS-D scores with 95% confidence interval related to COMT genotype in men and womenFigure 1
Mean HADS-D scores with 95% confidence interval 
related to COMT genotype in men and women. Num-
bers of participants are given. Gender comparison for each 
genotype was performed with Mann-Whitney U test.
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This is the first population-based study evaluating the
relationship between HADS and the Val158Met polymor-
phism. In a group of 5,531 unselected adults, no signifi-
cant association was found with anxiety and depression
using the cut-off score ≥ 8 for HADS-A and HADS-D.
When employing the alternative cut-off score ≥ 11,
depression was less likely among men with the Met/Met
genotype than among men with the Val/Val genotype.
Val/Val individuals would be expected to have lower
transsynaptic catecholamine levels, due to their high
COMT enzyme activity. Such depletion of transsynaptic
catecholamine neurotransmitters, like dopamine and
noradrenaline, may very well influence susceptibility to
depression in this genotype group [3]. Because this associ-
ation was based on a very small number of cases, it may
be incidental, and therefore needs to be interpreted with
some caution. Interestingly, however, an association
between Val/Val genotype and major depression with
early onset has been reported in a multicenter study of
various European populations [3]. In contrast to these
findings, Ohara et al. found higher frequencies of the Met
allele in depressed Asian patients compared with a control
group [4]. However, because differences in COMT geno-
type distribution between ethnic groups are considerable,
a finding in one group might not be valid for other groups
[23].
Our failure to establish a significant association between
anxiety and the Val158Met polymorphism is supported
by previous research on various forms of anxiety [6,24],
including a meta-analysis on panic disorder [8]. Conflict-
ing results have been found in other studies. Most of these
Table 2: Distribution of HADS-score related to genotype of COMT in men and women.
Met/Met Val/Met Val/Val
No. % No. % No. %
Genotypes
Men
Controls (HADS-D< 8 + HADS-A < 8) 579 33.9 829 48.5 301 17.6
HADS-D ≥ 8 71 30.2 122 51.9 42 17.9
HADS-D ≥ 111 13 18.3 40 56.3 18 25.4
HADS-A ≥ 8 70 29.7 123 52.1 43 18.2
HADS-A ≥ 11 16 25.0 39 60.9 9 14.1
Combined (HADS-D ≥ 8+HADS-A ≥ 8) 30 30.9 53 54.6 14 14.4
Unclassified (incomplete data) 29 29.5 226 51.6 83 18.9
Women
Controls (HADS-D< 8 + HADS-A < 8) 549 30.6 889 49.5 358 19.9
HADS-D ≥ 8 96 35.2 132 48.4 45 16.5
HADS-D ≥ 111 27 32.9 37 45.1 18 22.0
HADS-A ≥ 8 125 34.2 175 47.8 66 18.0
HADS-A ≥ 11 46 37.4 53 43.1 24 19.5
Combined (HADS-D ≥ 8+HADS-A ≥ 8) 47 37.3 55 43.7 24 19.0
Unclassified (incomplete data) 227 32.4 338 48.2 136 19.4
Alleles Met Val
Men
Controls 1987 58.1 1431 41.9
HADS-D ≥ 8 264 56.2 206 43.8
HADS-D ≥ 112 66 46.5 76 53.5
HADS-A ≥ 8 263 55.7 209 44.3
HADS-A ≥ 11 71 55.5 57 44.5
Combined (HADS-D ≥ 8+HADS-A ≥ 8) 113 58.2 81 41.8
Unclassified (incomplete data) 484 55.3 392 44.7
Women
Controls 1987 55.3 1605 44.7
HADS-D ≥ 8 324 59.3 222 40.7
HADS-D ≥ 112 91 55.5 73 44.5
HADS-A ≥ 8 425 58.1 307 41.9
HADS-A ≥ 11 145 58.9 101 41.1
Combined (HADS-D ≥ 8+HADS-A ≥ 8) 49 59.1 103 40.9
Unclassified (incomplete data) 792 56.5 610 43.5
1. Male cases with HADS-D ≥ 11 versus male controls: p = 0.01.
2. Male cases with HADS-D ≥ 11 versus male controls: p = 0.006Page 5 of 8
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anxiety and panic disorder [5,25-27], whereas Woo et al.
showed a Met/Met genotype predominance in patients
with panic disorder [7].
The strength of this study was that our sample was drawn
from a large and unselected population, which consisted
of ethnically homogenous Norwegian individuals.
Because no information about ethnic backgrounds was
available in our data file, the relatively few numbers of
non-Caucasians subjects could not be excluded in the sta-
tistical analyses. Because the distribution of the two
COMT alleles differs between different ethnic groups [23],
the risk of bias caused by ethnical admixture could not be
ruled out.
The fact that psychiatric questions were not the primary
objectives of HUNT made interest-related bias less likely.
Some research has indicated that people with psychiatric
disorders are over-represented among non-responders in
studies of the general population [28]. This could be a
weakness, since 30% of invited individuals did not attend
[16]. But according to a study on non-attendants, health
related reasons for not attending were unlikely among
individuals below 70 years of age [17]. Our sample of
more than 4000 individuals should have sufficient power
to detect a difference of clinical interest in prevalence of
depression and anxiety between genotypes. Because of the
large sample size, we had enough power to present sepa-
rate analyses by gender.
HADS, used in many former studies of the HUNT popula-
tion [20,29-31], has good reliability and validity com-
pared with other symptom scales of depression and
anxiety [10-15]. Several articles have stated its suitability
in samples from the general population with the potential
to intercept undiagnosed- and untreated cases with
depression and/or anxiety [9,11,15]. Such cases may have
been missed in previous case-control studies examining
the relationship between the Val158Met polymorphism
and anxiety and/or mood disorders [3-8,24,25,32,33]. In
addition, diagnostic differences also exist, because most
previous studies have selected cases according to DSM-IV
or ICD-10 categories. However, the use of rigid diagnostic
criteria may fail to capture a potential genetic predisposi-
tion, and more and more studies have taken this into
account by also looking at psychological traits or interme-
diate phenotypes instead of standard diagnoses [34-36].
HADS based diagnoses of depression and anxiety disorder
do not correspond exactly to any of the specific diagnoses
of DSM-IV or ICD-10, but HADS includes certain ICD-10
features [11,20]. In particular, HADS-D focuses on anhe-
donia, by some viewed as a core symptom of depression
[14], while the HADS-A subscale mainly captures features
of generalized anxiety [21]. Recently, it has been suggested
that HADS-A covers two dimensions, i.e. negative affectiv-
ity and autonomic arousal [37]. A separate evaluation of
these two dimensions was not possible, and as a conse-
quence, we can not rule out a possible positive association
between the Val158Met polymorphism and negative
affectivity or autonomic arousal, respectively.
Our study could not confirm any clear association
between the Val158Met polymorphism and anxiety or
depression measured by HADS. However, a number of
functional polymorphisms in- or close to the COMT gene
have been described, and some recent studies have looked
at multiple single nucleotide polymorphisms (SNPs) and
different COMT haplotypes in relation to psychiatric phe-
notypes [38,39], and interaction between the COMT gene
and other genes [26,33]. Due to lack of financial- and per-
sonnel resources we did not assess additional SNPs within
the COMT gene or in other genes. As a consequence, we
were unable to evaluate the influence of haplotypes of the
COMT gene or possible interactions with other genes on
HADS.
Conclusion
In this population-based study on 5531 unselected Nor-
wegian adults no clear association between the Val158Met
polymorphism and depression and anxiety was revealed.
Among men the Met/Met genotype was associated with
lower prevalence of depression when using a high cut-off
score, but this may be an incidental finding.
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